

FORM 7
MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Nass Valley Gateway Ltd. (the “Company” or “Nass Valley”)**.

Trading Symbol: **NVG**

Number of Outstanding Listed Securities: **312,143,477 common shares**

Date: **April 4, 2019**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Nass Valley’s common shares are listed for trading on the CSE under the symbol “NVG” and are co-listed on the “open market” of the Frankfurt Stock Exchange, trading under the symbol “3NVN”. On March 22, 2018 the Company executed the Definitive Acquisition and Share Exchange Agreement (“DASE-Agr”) with Advanced Bioceuticals Limited (“ABL”), a New Jersey Limited Liability Company, with company registration number 0450237249, to acquire 100% ownership interest in ABL and its wholly owned subsidiary Pro-Thotics Technology Inc. (“PTI”) through a share exchange.

Pursuant to the DASE-Agr, the consideration for the 100% ownership interest of ABL and including ABL's wholly owned subsidiary Pro-Thotics Technology, Inc. was 400,000,000 common shares of NVG at a deemed price of \$0.10 per common share to be issued to the shareholders of ABL.

On February 27, 2019, following an internal Listing Application Review, the CSE approved the fundamental change of the Issuer for listing subject to Completion of the acquisition of ABL and the Completion all outstanding CSE application documentation and payments.

Nass Valley and the owners of ABL amended the DASE-Agr on March 19, 2019 by changing the consideration for the 100% ownership interest of ABL and PTI from 400,000,000 common shares of NVG at a deemed price of \$0.10 per share to 280,000,000 common at a deemed price of \$0.1429 per share. As a result of the amendment the shareholders of ABL own 85.06% of Nass Valley's outstanding share capital instead of originally proposed 89,27%.

Under the amended DASE-Agr, ABL's shareholders agreed that all 280,000,000 issued common shares are subject to the four months hold period pursuant to the Canadian securities laws. 266,000,000 of those issued shares are also subject to resale restrictions prescribed by the U.S. securities laws and cannot be resold during the next 12 months without strict compliance under the U.S. securities laws. In addition, 261,400,000 common shares are also subject to an escrow agreement, a copy of which is available under the profile of the Company on www.sedar.com.

2. Provide a general overview and discussion of the activities of management.

The Company issued the in Section 1. mentioned shares to the shareholders of ABL in exchange for the transfer of full ownership of ABL and PTI and Assets.

As the Nass Valley's controlling shareholders and its acquired assets are respectively residents and located in the U.S., the Company is now considered a "Non-foreign private issuer" under the United States United States *Securities Law Act of 1933* (the "Securities Act") and will likely be classified as a "domestic issuer" pursuant to the Securities Act. Nass Valley will now have to comply with securities laws of the United States in addition to complying with the securities laws of applicable Canadian provinces.

On March 26, 2019 Nass Valley announced the appointment of Mr. John Affenita as Director and CEO, Dr. Samuel Alawieh as Director and COO and Mr. Michael Semler as CFO. All three gentlemen are citizens of the United States and as referred in the above announcement have extensive experience in the in the healthcare and wellness business through their past occupations.

3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

NONE

4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Through its wholly owned subsidiaries Nass Valley will now follow up on relationships and contacts it may have lost and/or couldn't execute during the approval process of its fundamental acquisition.

5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

NONE

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

There were no acquisitions or dispositions by the Issuer in addition to its latest approved acquisition of Advanced Bioceuticals Limited and Pro-Thotics Technology Inc.

7. Describe the acquisition of new customers or loss of customers.

Nass Valley is confident that it has not lost any of its PTI-Business as described in section 4. and it also confident that it may be able to announce very shortly the replacement of those potential customers of its ABL-Business which it may have has lost due to the approval process of its fundamental acquisition of Advanced Bioceuticals Limited.

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

NONE

9. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

As describe in its submitted Listing Statement for the approved fundamental acquisition, previously unpaid officers and consultants will be paid as of the approval date of the transaction.

10. Report on any labour disputes and resolutions of those disputes if applicable.

None.

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

NONE

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

The Issuer has no debts outstanding and with its present adjusted management structure will have sufficient working capital to remain in good standing with all regulatory authorities.

14. Provide details of any securities issued and options or warrants granted

Security	Number Issued	Details of Issuance	Use of Proceeds
Common shares	280,000,000	Consideration for the approved “fundamental acquisition”	Acquisition of 100% interest in Advanced Bioceuticals Limited and Pro-Thotics Technology Inc.
Options	None		N/A
Warrants	None		N/A

15. Provide details of any loans to or by Related Persons.

The Issuer did not receive any loans during the months of February 2019 and has no loans outstanding either to Related or Unrelated Persons.

16. Provide details of any changes in directors, officers or committee members.

NONE

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

Nass Valley Gateway has historically relied upon equity financings to satisfy its capital requirements and will continue to depend on equity capital to finance its activities for its planned growth. Although the Company is convinced that its latest acquisitions will generate a positive cash flow, Nass Valley will still need additional capital to finance the commercialization of its planned technology projects. Such additional capital will have to be derived partly from the exercise of outstanding warrants, options but also from the cash flow derived through operations including the completion of measured equity financings or convertible debentures.

Even though the Issuer has been successful in the past in financing its activities and has increased its potential of completion such financings through the sale of equity securities through its latest acquisitions, there is no assurance that additional funding will be available for future development of its projects. The Issuer's ability to arrange additional financing in the future will depend, in part, on the prevailing capital market conditions and success in its proposed projects.

There can be no assurance that continual fluctuations in the Company's share prices will not occur or that such fluctuations will not affect the ability of Company to raise additional equity funding, and if at all, can be achieved via financial instruments avoiding significant additional dilution to its existing shareholders. Any quoted market for the common shares will be subject to market trends generally, notwithstanding any potential success of the Issuer in creating revenue, cash flows or earnings.

Although the Company believes that the operations of its acquired subsidiaries are in material compliance with current applicable regulations, no assurance can be given that a future change of laws will not result in a curtailment of production or a material adverse effect on the Company's overall business, financial condition and results of operations.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **April 4, 2019.**

Dieter Peter
Name of Director or Senior
Officer

"Dieter Peter"
Signature
Chairman & Director
Official Capacity

	For Month Ended March 31, 2019	Date of Report YY/MM/D 19/04/04
Issuer Address 170-422 Richards Street		
City/Province/Postal Code Vancouver, B.C. V6B 2Z4	Issuer Fax No. (604) 568-9844	Issuer Telephone No. +1 (516) 680-0433
Contact Name Dieter Peter	Contact Position Chairman & Director	Contact Telephone No. +1(604) 617-6794
Contact Email Address info@nassvalleygateway.com	Web Site Address www.nassvalleygateway.com	